The inheritance of most forms of epilepsy is usually considered to be multifactorial, although a number of single gene causes are known. Most previous studies of epilepsy genetics have implicated ion channel genes or ligand receptors. In a previous study of children with adverse effects of prenatal exposure to antiepileptic drugs, we noted an increased frequency of the methylene tetrahydrofolate reductase (MTHFR) 677C>T polymorphism in the mothers. To investigate this further, a new cohort of women with epilepsy has been identified from maternity hospital records and genotyped for polymorphisms in MTHFR, serine hydroxymethyl transferase (SHMT1), methionine synthase (MTR) and methionine synthase reductase (MTRR). Healthy blood donors were genotyped as controls. The frequency of the MTHFR 677TT genotype was significantly higher in women with idiopathic generalised epilepsy than in healthy controls ( p = 0.012, OR 2.26, 95%CI 1.13-4.51). No association was detected for the other polymorphisms tested. The MTHFR 677C>T polymorphism may be a susceptibility factor for epilepsy, and its higher frequency in women with epilepsy may contribute to the increased risk of malformation in children of women with epilepsy.
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Introduction
Epilepsy is a common disorder affecting around 5 per 1000 individuals under the age of 64. 1 It is phenotypically and aetiologically heterogeneous. If there is evidence of brain injury, tumour, or an underlying disorder affecting the brain such as tuberous sclerosis, the epilepsy may be classified as symptomatic or secondary. Often, no brain lesion can be identified, and the epilepsy is said to be ''idiopathic''. [2] [3] [4] Inherited forms of idiopathic epilepsy due to mutation in a single gene have been identified, but familial recurrence rates for idiopathic epilepsies in general, and the heterogeneity of epilepsy phenotype within families suggest complex inheritance (involvement of many genes and probably nongenetic factors). Genome-wide scans and other studies aimed at finding susceptibility genes for idiopathic epilepsy, have implicated mostly ion channel, and ligand receptor genes. 4 Two small studies also showed an association between the common 677C>T polymorphism in the methylene tetrahydofolate reductase (MTHFR) gene and epilepsy. 5, 6 In a previous study, 7 we found an apparent association between maternal MTHFR genotype and serious adverse effects in the child of prenatal antiepileptic drug (AED) exposure, but as there was no control group of normal children with prenatal AED exposure, the association detected could have been with maternal epilepsy. Although most of the mothers had epilepsy, a few had been prescribed AEDs for other disorders. In order to investigate whether MTHFR or other folate pathway gene polymorphisms are associated with epilepsy, we undertook a further study in a population-based cohort of women with epilepsy ascertained through Aberdeen Maternity Hospital records and report the findings.
Methods

Clinical recruitment and classification
In North-East Scotland, high risk pregnancies (including those in women with epilepsy) are managed at Aberdeen Maternity Hospital. Four hundred and eighty-six mothers who were prescribed AEDs during a pregnancy between 1 January 1976 and 31 December 2002 were identified from hospital records. 8 Of these, 333 were contactable, and 200 agreed to participate. A trained research nurse undertook structured interviews recording maternal medical history, family history, and AED use in each pregnancy. Epilepsy diagnosis and investigations were reviewed in the hospital records. Epilepsy classification followed the principles outlined by 
Statistical analysis
Genotype frequencies in mothers with epilepsy were compared with female healthy blood donor controls using a case-control study design. Significance was assessed using the x 2 test or Fisher twotailed test and odds ratios with 95% confidence intervals were calculated. The data for MTHFR 677C>T is subdivided by epilepsy category (Table 1) , whereas data for other genotypes is shown for idiopathic generalised epilepsy (IGE) only (Table 2) . MTHFR 677C>T/1298A>C haplotypes for IGE cases and controls were inferred using an online implementation of a maximum likelihood method (HAP Version 3, http://research.calit2.net/hap/ WebServer.htm), 15 and odds ratios with 95% confidence intervals calculated for haplotypes and diplotypes (Tables 3 and 4 ). To check consistency of haplotype inference, a similar analysis was undertaken using an alternative algorithm and software implementation (Phase version 2.1 16, 17 ), but this gave similar results (data not shown).
The study was reviewed and approved by the NHS Grampian Local Research Ethics Committee.
Results
The majority of women tested had idiopathic generalised epilepsy (Table 1) . MTHFR 677C>T genotype frequencies were significantly different from controls in this group. The proportion of TT homozygotes and CT heterozygotes was greater than in controls, and the frequency of TT homozygotes Haplotype analysis was undertaken for the MTHFR genotypes in the IGE mothers and controls. The frequency of the 677T/1298A haplotype was significantly greater in IGE cases than controls, whereas the 677C/1298A haplotype was significantly less common in cases (Table 3) . Analysing diplotypes, the frequency of individuals homozygous for both 677T and 1298A was significantly greater in IGE cases than in controls, and the frequency of individuals homozygous for both common alleles (677C and 1298A) was significantly lower (Table 4) . Analysing 677CC homozygotes and 1298AA homozygotes independently, the IGE group had fewer 677CC homozygotes than the control group ( p = 0.01, OR 0.58, 95%CI 0.39-0.9) but there was no significant difference for 1298AA ( p = 0.501, OR 0.87, 95%CI 0.57-1.34).
Discussion
Although there are a number of monogenic epilepsy syndromes (for example, autosomal dominant frontal lobe epilepsy, benign familial neonatal seizures) most forms of idiopathic epilepsy probably have a polygenic form of inheritance. 4 The final epilepsy phenotype is likely to be influenced by the interaction of several genes, and perhaps non-inherited factors. Some of these genes may be regarded as susceptibility genes, and could also affect risk of developing symptomatic epilepsy after brain injury. Most studies of epilepsy genetics have concentrated 272 J.C.S. Dean et al. on voltage or ligand-gated ion channel genes, and genes involved in intracellular signalling, or axonal guidance. 4 Genome-wide scans have usually implicated such genes, 19, 20 although recently one study implicated a metabolic enzyme, malic enzyme 2 in non-specific epilepsy susceptibility. 21 Two previous studies have implicated MTHFR as a susceptibility factor for epilepsy--one study demonstrated an excess of MTHFR 677TT homozygotes in men and women attending an epilepsy clinic in Korea, 5 while the other found an excess of MTHFR 677T alleles amongst patients with symptomatic epilepsy, but not in those with idiopathic epilepsy. 6 Numbers in this second study were small. Our genotype frequency results suggest an association between the MTHFR 677CT and TT genotypes and idiopathic generalised epilepsy in fertile women, although the association is still significant when mothers with symptomatic epilepsy are included (Table 1) . Our data does not show a significant association with symptomatic epilepsy separately, but the number in this subgroup is small. Case selection could have influenced these results, in that our cases were all mothers, and only 51% of those eligible could be genotyped successfully. There is no reason to believe that cases were more or less willing to give a sample than controls, or that this factor is associated with MTHFR genotype, but these possibilities cannot formally be excluded. Our control group is age and gender matched to the cases and comes from a similar ethnic background, but we do not know their reproductive histories. However, our study provides similar findings to previous studies in other groups of patients with epilepsy, which included males and did not select through an obstetric route, suggesting that the association between MTHFR 677C>T and epilepsy may be real.
The mechanisms behind this association are unclear. The polymorphism is associated with a twofold increase in plasma homocysteine in the homozygous state, 9 particularly in those taking AEDs, 5 although unfortunately levels were not measured in this study. Patients with seizures due to autosomal recessive MTHFR deficiency have a 10-fold increase in plasma homocysteine, but also have leukoencephalopathy and other neurological abnormalities 22 --the contribution of homocysteine level to seizure risk is uncertain.
Homozygosity for the 677T allele interacts with dietary folic acid depletion to cause leucocyte DNA hypomethylation in healthy adults. [23] [24] [25] [26] Homozygosity for the 1298C allele may not have the same effect. 25, 26 Activity-dependent regulation of expression of the neurotrophin BDNF, thought to be involved in epilepsy susceptibility, relies on DNA methylation. 27, 28 MTHFR 677C>T could affect epilepsy susceptibility by enhancing BDNF expression inappropriately through DNA hypomethylation.
No association with the MTHFR 1298A>C polymorphism was detected in our study, which is compatible with this hypothesis. MTHFR haplotype analysis (Table 3) demonstrated an association with the 677T allele in cis with 1298A, and suggests a protective effect of 677C in cis with 1298A. The occurrence of the two reduced activity alleles (677T and 1298C) in cis was not inferred in the cases, and appeared at very low frequency in the controls. This is compatible with previous studies suggesting strong linkage disequilibrium (LD) between these two polymorphisms, which have apparently arisen on different ancestral chromosomes. 11, 29 Any weak effect of 1298C could therefore have been masked by the strong LD with 677T. The diplotype analysis (Table 4 ) also suggested an association between IGE and homozygosity for 677T ( p = 0.0223), but did not suggest any significant association with homozygosity for 1298C ( p = 0.973), or with compound heterozygosity ( p = 0.058). In addition, although homozygosity for both 677C and 1298A may have a protective effect against IGE ( p = 0.01), this effect appears to be due to the 677C allele ( p = 0.01).
The apparent association with MTHFR 677C>T could be due to linkage disequilibrium with another gene located nearby on chromosome 1p36. A voltage gated potassium channel gene, KCNAB2, maps to chromosome 1p36, and deletion of this region is associated with infantile spasms 30 but other genes are also lost in the deletion, and the relevance of KCNAB2 to idiopathic epilepsy is unknown. If the MTHFR 677C>T polymorphism was acting as a marker for an adjacent gene, similar effects would be expected on MTHFR 1298A>C frequency. The absence of any detectable effect for 1298C using genotype, haplotype and diplotype analysis suggests although does not prove that 677T may be causative.
Genome-wide scans have failed to implicate this chromosome region in epilepsy susceptibility previously, but these studies have tended to select multiplex, multigenerational families, often identified through a proband with juvenile onset epilepsy in order to enrich for potentially Mendelian epilepsy, and used linkage-based methods more adapted to identifying dominant genes. [19] [20] [21] Our study did not deliberately select such families, but the average onset age of our cases was 14.8 years, and 38% had a family history of epilepsy, comparable with other studies. It may be that the effect of homozygosity for MTHFR 677C>T as a susceptibility factor is too weak to detect in a conventional linkage scan--the only other study identifying a recessive susceptibility factor for epilepsy (malic enzyme) also used association-based methods as well as linkage. 21 Although the MTHFR 677C>T polymorphism is the most widely studied genetic variant in the folate pathway, variants in other genes affecting folate metabolism could also contribute. We therefore chose to test three other polymorphisms in folate pathway genes for association with epilepsy. A key role of MTHFR in folate metabolism is to provide the 5-methyltetrahydrofolate required by MTR for the remethylation of homocysteine to methionine 31 ( Fig. 1) . The 677C>T polymorphism results in a thermolabile enzyme with reduced activity, while the second MTHFR polymorphism studied, 1298A>C causes a milder impairment of enzyme activity.
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MTR activity is controlled by MTRR and, like MTHFR, common polymorphisms in these genes have been associated with malformations such as neural tube defects in children. 32 The polymorphisms chosen for study might be predicted to reduce the availability of methionine as a substrate for methylation, as well as increasing homocysteine levels, in a similar way to MTHFR 677C>T. SHMT1 reversibly catalyses the production of 5,10-methylene tetrahydrofolate, the substrate for both MTHFR and thymidylate synthase, from tetrahydrofolate, and may act as a metabolic switch between methionine synthesis and thymidine synthesis. 33 The 1420C>T polymorphism in this gene alters the distribution of folate derivatives. 12 The distributions of genotypes and allele frequencies for MTHFR 1298A>C, MTR 2756A>G, MTRR 66A>G and SHMT1 1420C>T in the women with epilepsy studied were not significantly different from age matched controls, providing no evidence that they are involved in epilepsy susceptibility. This lack of association could be because they cause less interference with methionine availability or homocysteine levels than the MTHFR 677C>T polymorphism, and measurement of homocystine and methionine levels in the mothers and controls might have clarified this point. MTHFR 677C>T, 1298A>C and the MTR and MTRR polymorphisms all show an association with neural tube defect in children. Possibly the developing embryo is more sensitive to perturbations of this pathway than the adult brain, or perhaps MTHFR has an additional role in the development or function of the brain which is yet to be determined.
Including this one, three studies have now implicated the MTHFR 677C>T polymorphism in epilepsy susceptibility, and the association could provide part of the explanation for the increased frequency of malformation in children of mothers with epilepsy. 7 Clarification of the degree of risk, implications for management, and underlying pathogenetic mechanisms await further studies. Figure 1 BHMT, betaine homocysteine methyl transferase; MAT, methionine adenosyl transferase; MT, methyl transferase; SAHH, s-adenosyl homocysteine hydrolase; MTHFR, 5,10-methylene tetrahydrofolate reductase; MTR, methionine synthase; MTRR, methionine synthase reductase; DHFR, dihydrofolate reductase; TS, thymidylate synthase; SHMT, serine hydroxy methyl transferase 1; CH 3 THF, 5-methyl tetrahydrofolate; THF, tetrahydrofolate; DHF, dihydrofolate; CH 2 THF, 5,10-methylene tetrahydrofolate.
